Documentos relacionados

1. Chronic active Epstein-Barr virus disease originates from infected hematopoietic stem cells.
2. A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis.
3. [Value of metagenomic next-generation sequencing in children with hemophagocytic syndrome with central nervous system involvement].
4. Clinical and genetic characterization of Epstein-Barr virus-associated T/NK-cell lymphoproliferative diseases.
5. Use of extracorporeal immunomodulation in a toddler with hemophagocytic lymphohistiocytosis and multisystem organ failure.
6. [Clinical features and prognostic factors of severe hemophagocytic syndrome in children].
7. Characteristics of Virology and Immune Inflammation of Epstein-Barr Virus Infection Related Non-Neoplastic Diseases in Children.
8. Spectrum of neuroradiological manifestations in primary hemophagocytic lymphohistiocytosis: a comparative study of EBV-induced versus non-EBV-induced forms in 75 genetically confirmed pediatric cases.
9. A case of VEXAS syndrome associated with EBV-associated hemophagocytic lymphohistiocytosis.
10. An analysis of sintilimab combined with ruxolitinib as compassionate therapy for 12 adults with EBV-associated hemophagocytic lymphohistiocytosis.